Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.
ZimVie Inc. (Nasdaq: ZIMV) is a leading global life sciences company specializing in the dental and spine markets. Formed in March 2022 as an independent spin-off from Zimmer Biomet, ZimVie focuses on developing, manufacturing, and delivering a diverse portfolio of innovative products designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures.
Company Segments:
- Spine Products Segment: ZimVie offers an array of spine solutions, including implants, surgical tools, and bone graft substitutes. Significant advancements include the launch of the 4.5mm Mobi-C Cervical Disc, which provides pain relief and motion preservation for cervical disc degeneration.
- Dental Products Segment: The company delivers comprehensive dental solutions, including implants and digital care management systems. ZimVie is committed to driving peri-implant health and immediacy through its innovative dental product lines.
Recent Achievements:
- In October 2023, ZimVie celebrated the first U.S. implantation of its 4.5mm Mobi-C implant.
- In December 2023, the company received FDA clearance for its Vital™ Spinal Fixation System, designed for use with Brainlab Spine & Trauma Navigation.
Current Projects:
- ZimVie is actively co-marketing Brainlab Spine & Trauma Navigation alongside its Vital and Virage product lines, with plans to expand further in 2024.
- The company is also focused on the strategic sale of its spine business to H.I.G. Capital, expected to close in the first half of 2024. This move aims to streamline operations and sharpen focus on the dental sector.
Financial Health:
ZimVie continues to navigate its financial landscape with strategic initiatives like debt reduction and reallocation of resources to higher-growth dental markets. The company has paid down significant debt while maintaining a robust portfolio of products supported by extensive clinical evidence.
Partnerships:
ZimVie collaborates with leading organizations like Brainlab to enhance its product offerings, ensuring cutting-edge solutions in spine and dental care. These partnerships enable ZimVie to remain at the forefront of technological advancements in the medical device industry.
ZimVie Inc. (Nasdaq: ZIMV) reported its FY 2022 financial results, with third-party net sales of $909.5 million, reflecting a 9.8% decline compared to FY 2021. The company recorded a net loss of ($63.9 million) and a net loss margin of (7.0%). Adjusted net income rose to $47.9 million with adjusted diluted EPS at $1.84. The fourth quarter saw net sales of $228.2 million, down 12.4% year-over-year. Key developments included new product launches, an expanded policy decision affecting 4+ million lives, and a successful ERP transition. Guidance for FY 2023 predicts net sales between $825 million and $850 million.
ZimVie Inc. (Nasdaq: ZIMV) announced advancements in its digital dentistry platform with the launch of two new modules: the RealGUIDE CAD and FULL SUITE. The CAD module enhances restorative workflows with advanced design capabilities, allowing users to create complex dental structures easily. The FULL SUITE integrates existing modules into a comprehensive system, facilitating collaborative implant planning and guided surgery. These innovations will debut at LMT Lab Day in Chicago and expand to Europe at the International Dental Show next month. This strategic enhancement aims to streamline operations for dental practices and support successful patient outcomes.
ZimVie Inc. (Nasdaq: ZIMV) announced it will report its financial results for the fourth quarter and full year 2022 on March 1, 2023, after market close. A conference call will follow at 4:30 p.m. Eastern Time. Interested parties can register for the call. ZimVie specializes in dental and spine markets and became an independent entity in March 2022, focusing on its product portfolio to serve customers in over 70 countries.
ZimVie Inc. (Nasdaq: ZIMV) announced a significant milestone, with over 200,000 Mobi-C Cervical Discs implanted globally since its FDA approval in 2013 for cervical disc replacement. This achievement aligns with the ten-year anniversary of the device's FDA clearance, which marked its superiority over fusion surgeries at the seven-year mark, and continued patient-reported outcomes at ten years. ZimVie highlights this success as part of its 'Year of Mobi-C' initiative, reinforcing its commitment to advancing cervical disc technology and improving patient care.
ZimVie Inc. (Nasdaq: ZIMV), a leader in life sciences within the dental and spine markets, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Vafa Jamali is scheduled to speak on January 11, 2023, at 3:00 p.m. PT. The presentation will be accessible via a live and archived webcast. Founded in March 2022 as a spin-off from Zimmer Biomet, ZimVie provides a wide range of dental and spine solutions across over 70 countries, focusing on product innovation and clinical evidence.
ZimVie Inc. (Nasdaq: ZIMV) reported third quarter 2022 financial results with third party net sales of $213.3 million, a decrease of 10.6% year-over-year. Net income reached $0.8 million, compared to a net loss of $30.2 million in Q3 2021. Adjusted diluted EPS was $0.49. The dental segment saw a slight decline of 3.9%, while the spine segment dropped 16.4%, influenced by market exits and competitive pressures. Cash reserves were $116.0 million. The company reaffirmed full-year guidance for net sales of $915 to $930 million and adjusted EPS of $1.80 to $2.00.
ZimVie has launched the TSX Implant, a significant innovation in its dental solutions portfolio. Designed for immediate extraction and loading, the TSX Implant aims to enhance peri-implant health and improve placement predictability in various bone types. This implant integrates over 20 years of clinical data, emphasizing features that promote long-term osseointegration and stability. The implant was recently introduced at the American Academy of Periodontology’s annual meeting, showcasing ZimVie’s commitment to advancing digital dental workflows and improving patient outcomes.
ZimVie Inc. (Nasdaq: ZIMV) will announce its third quarter 2022 financial results on November 9, 2022, after market close. Following the results, the management will conduct a conference call at 4:30 p.m. Eastern Time. Interested participants can register online and are encouraged to do so at least 15 minutes prior to the call. ZimVie specializes in dental and spine markets, providing a range of products for various spine pathologies and dental procedures. The company became an independent entity in March 2022, focusing on strategic growth in its sectors.
ZimVie Inc. (ZIMV) has announced the launch of the Virage Navigation System, a new tool designed for spinal surgery that enhances pedicle screw navigation across the entire spine. This system features a 360° Omnidirectional Extreme-Angle Screw allowing for improved screw placement with reduced operating times. It integrates with existing navigation systems, complementing the prior Vital Navigation System. This innovation reflects ZimVie’s commitment to advancing spinal technologies and enhancing surgical outcomes.
ZimVie Inc. (Nasdaq: ZIMV), a leader in dental and spine markets, announced its participation in Morgan Stanley's 20th Annual Global Healthcare Conference in New York. Management, including President Vafa Jamali and CFO Rich Heppenstall, will present on September 13, 2022, at 7:20 AM EDT. The event will be accessible via a live and archived webcast. Established in March 2022 as a spin-off from Zimmer Biomet, ZimVie is dedicated to enhancing life sciences with innovative dental and spine solutions, serving over 70 countries worldwide.
FAQ
What is the current stock price of ZIMVIE (ZIMV)?
What is the market cap of ZIMVIE (ZIMV)?
What does ZimVie Inc. specialize in?
When was ZimVie founded?
What are the two main operating segments of ZimVie?
What is the Mobi-C Cervical Disc?
What recent FDA clearance did ZimVie receive?
Who is ZimVie selling its spine business to?
How does ZimVie plan to use the proceeds from the spine business sale?
What are some of ZimVie's partnerships?
Where is ZimVie headquartered?
What markets does ZimVie serve?
